RBC Capital Lifts PT on Legend Biotech Corporation (LEGN) to $77 From $75

Legend Biotech Corporation (NASDAQ:LEGN) is one of the most promising future stocks according to Wall Street analysts. On August 12, RBC Capital raised the firm’s price target on Legend Biotech Corporation (NASDAQ:LEGN) to $77 from $75, keeping an Outperform rating on the shares.

The analyst told investors in a research note that the Q2 beat by Legend Biotech Corporation (NASDAQ:LEGN) suggests continuing strong demand and successful manufacturing for Carvykti, supporting sustainable growth for the franchise.

The firm added that it continues to anticipate growth in the US, with additional acceleration expected ex-US. It also sees several tailwinds for Legend Biotech Corporation (NASDAQ:LEGN), including pull-through of 5-year OS data.

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.

While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.